Novel natriuretic peptides: new compounds and new approaches.
The natriuretic peptides (NPs) are a group of structurally similar yet genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Since the discovery of atrial natriuretic peptide in 1981, the diagnostic, prognostic, and therapeutic significance of NPs have been studied extensively in relation to heart failure. Indeed, it now is understood that a hallmark of heart failure is the activation of the cardiac endocrine system, in particular the natriuretic peptide family including atrial natriuretic peptide and B-type natriuretic peptide. Currently, the only approved therapeutic application for NPs is the intravenous treatment of acute decompensated heart failure. However, in recent years there has been considerable research aimed at creating novel NPs and administering them via novel routes. This review focuses on the novel NPs that have been created and on novel approaches for their administration.
Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Mark W
MW
Vogel
Horng H
HH
Chen
D000284:Administration, Oral; D017398:Alternative Splicing; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage; D045265:Natriuretic Peptides / Q000008:administration & dosage*; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D045265:Natriuretic Peptides; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor